BioSpace News Archive

Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-generation small molecule drugs, today announced the appointment of Robert J. Buckley as its Chief People Officer.

Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on April 20, 2022 to close the consolidated financial statements for the year ending December 31, 2021, announces its full-year results for 2021 and business indicators for the first quarter of 2022.

C2N Diagnostics, a leader in advanced brain health diagnostics, announced today that the Journal of the American Medical Association Network Open, a peer-reviewed medical journal from the American Medical Association, has published the combined results from two independent studies for the PrecivityAD™ blood test, which aids healthcare providers in diagnosing Alzheimer’s disease.

Pfizer Canada ULC is recalling all lots of the prescription drug Accupril in 10 mg, 20 mg and 40 mg strengths due to the presence of a nitrosamine impurity above the acceptable level.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of new and updated websites for its two products, Ameluz® and Xepi®.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended March 31, 2022 after the close of the market on Thursday, May 5, 2022.

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 12, 2022.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Avantor, Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.78 per share to holders of its 6.250% Series A Mandatory Convertible Preferred Stock with a liquidation preference of $50, payable on May 15, 2022 to holders of record on May 1, 2022.